Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Ïåäèàòðèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé ïåäèàòðîâ

Ôîðóì äëÿ îáùåíèÿ âðà÷åé ïåäèàòðîâ Ôîðóì ïðåäíàçíà÷åí òîëüêî äëÿ îáùåíèÿ âðà÷åé ìåæäó ñîáîé. Âîïðîñû ïàöèåíòîâ çàäàþòñÿ íà ôîðóìå Ïåäèàòðèÿ.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #136  
Ñòàðûé 05.01.2015, 19:47
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ëå÷åíèå ñðåäíåãî îòèòà ñ ïåðôîðàöèåé áàðàáàííîé ïåðåïîíêè

AFP-àññîöèaöèÿ àìåð.ñåìåéíûõ âðà÷åé
Treatment of Otitis Media with Perforated Tympanic Membrane

Äîêàçàòåëüíûé îòâåò(Evidence-Based Answer)
Îñòðûé ñðåäíèé îòèò ñ ïåðôîðàöèåé áàðàáàííîé ïåðåïîíêè ó äåòåé ñëåäóåò ëå÷èò ïåðîðàëüíûì àíòèáèîòèêîì. Ìåñòíûå öèïðîôëîêñàöèí / äåêñàìåòàçîí (Öèïðîäåêñ) ëó÷øå, ÷åì îðàëüíûé àìîêñèöèëëèí / êëàâóëàíîâàÿ êèñëîòà (Àóãìåíòèí) äëÿ ëå÷åíèÿ îñòðîãî ñðåäíåãî îòèòà ó äåòåé ñ òèìïàíîñòîìè÷åñêîé òðóáêîé(ïðè îòñóòñâèè âûñîêîé òåìïåðàòóðû) .Ìåñòíûå õèíîëîíîâûå àíòèáèîòèêè, ñ èëè áåç ìåñòíûõ êîðòèêîñòåðîèäîâ, ÿâëÿþòñÿ ëó÷øèì ëå÷åíèåì äëÿ õðîíè÷åñêîãî ãíîéíîãî ñðåäíåãî îòèòà.
ïîäðîáíåå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
èëè êðàòêèé ïåðåâîä íà ðóññêîì http://forums.rusmedserv.com/showthr...07#post2172907

Êîììåíòàðèè ê ñîîáùåíèþ:
SergMak îäîáðèë(à): Êàê ðàç î÷åíü àêòóàëüíî
Îòâåòèòü ñ öèòèðîâàíèåì
  #137  
Ñòàðûé 07.01.2015, 15:46
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
îðàëüíûå êîðòèêîñòåðîèäû â ëå÷åíèè àñòìû äîøêîëüíèêîâ

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
An Update on the Efficacy of Oral Corticosteroids in the Treatment of Wheezing Episodes in Preschool Children
.....International and national asthma guidelines recommend oral corticosteroids (OCSs) as a treatment for acute exacerbations that are not responsive to bronchodilators [National Asthma Education and Prevention Program, 2007; GINA, 2011]. There is substantial evidence for the efficacy of OCSs as a treatment for asthma exacerbations in school-aged children and adolescents, especially in the acute care setting where OCS treatment is associated with lower risk of relapse, fewer hospitalizations, and less need for β2-agonist treatments [Rowe et al. 2007]. Traditionally, wheezing episodes among preschool children have been treated with OCSs based on the established efficacy of OCSs among school-aged children and adolescents with asthma.....recent clinical studies questioned the benefits of OCSs as a treatment for acute wheezing in preschool children.
Conclusions and Recommendations

The vast majority of studies that evaluated the efficacy of OCSs among preschoolers with episodic wheeze failed to show benefit for this intervention .However, the exact role of OCSs remains uncertain as the current studies have limitations including relatively mild severity of exacerbations in the inpatient study, and low compliance in the largest outpatient study. Based on the current evidence we suggest that clinicians should continue treating these preschool children with inhaled β-agonists during acute exacerbations, but may consider avoiding OCS treatment in outpatient episodes provided adequate follow up is assured. As the data regarding lack of efficacy of OCS treatment is even more compelling among hospitalized toddlers, we suggest that clinicians may consider postponing OCS treatment in many hospitalized recurrent wheezers, and reserve the treatment for patients with a current or an anticipated severe clinical course including: patients requiring intensive-care admission, patient who do not improve appropriately with β-agonist treatment, and patients who have indicators of severe disease (e.g. persistent hypoxemia) or other significant medical history (such as chronic lung disease). Overall, the evidence base for the management of recurrent wheezing in preschool children is still incomplete, and additional RDBPCTs are required, mainly in the outpatient setting.

Ðóêîâîäÿùèå ïðèíöèïû Ìåæäóíàðîäíûå è íàöèîíàëüíûå àñòìû ðåêîìåíäóþò îðàëüíûå êîðòèêîñòåðîèäû â êà÷åñòâå ñðåäñòâà äëÿ ëå÷åíèÿ îáîñòðåíèé, êîòîðûå íå ðåàãèðóþò íà áðîíõîäèëàòàòîðû [National Asthma Education and Prevention Program, 2007; GINA, 2011]. Ñóùåñòâóåò ñóùåñòâåííûå äîêàçàòåëüñòâà îá ýôôåêòèâíîñòè ïåðîðàëüíûõ ÊÑÏ, êàê äëÿ ëå÷åíèÿ îáîñòðåíèé àñòìû ó äåòåé è ïîäðîñòêîâ øêîëüíîãî âîçðàñòà, îñîáåííî â óñëîâèÿõ èíòåíñèâíîé òåðàïèè, ãäå ëå÷åíèå ÎÊÑ ñâÿçàíî ñ áîëåå íèçêèì ðèñêîì ðåöèäèâà, ÷àñòîòû ãîñïèòàëèçàöèé è ìåíüøåé ïîòðåáíîñòüþ â β2-àãîíèñòîâ ëå÷åíèè.Òðàäèöèîííî, ýïèçîäû îäûøêè ñðåäè äåòåé äîøêîëüíîãî âîçðàñòà áûëè ïðîëå÷åíû ïåðîðàëüíûìè ÊÑÏ íà áàçå ñâåäåíèé îá ýôôåêòèâíîñòè ïåðîðàëüíûõ ÊÑÏ ñðåäè äåòåé øêîëüíîãî âîçðàñòà è ïîäðîñòêîâ ñ àñòìîé.....íåäàâíèå êëèíè÷åñêèå èññëåäîâàíèÿ ñòàâÿò ïîä ñîìíåíèå ïðåèìóùåñòâà ïåðîðàëüíûõ ÊÑ äëÿ ëå÷åíèÿ îñòðîãî ñâèñòÿùåãî äûõàíèÿ(îáñòð.áðîíõèòà -acute wheezing ) ó äåòåé äîøêîëüíîãî âîçðàñòà
ñòàòüþ ìîæíî ïðî÷èòàòü çäåñü [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Âûáîðî÷íûé ïîñèëüíûé ïåðåâîä http://forums.rusmedserv.com/showthr...=242045&page=6
Îòâåòèòü ñ öèòèðîâàíèåì
  #138  
Ñòàðûé 30.01.2015, 23:41
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,291
Ïîáëàãîäàðèëè 33,189 ðàç(à) çà 31,539 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
This is the first randomized placebo-controlled trial evaluating the novel coadministration of a probiotic and peanut OIT and assessing sustained unresponsiveness in children with peanut allergy. PPOIT was effective in inducing possible sustained unresponsiveness and immune changes that suggest modulation of the peanut-specific immune response.
---
J Allergy Clin Immunol. 2015 Jan 12.
Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #139  
Ñòàðûé 15.02.2015, 22:13
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íèçêèé óðîâåíü âèòàìèíà D ñâÿçàíû ñ ïîâûøåííûì ðèñêîì ðàííåãî íåîíàòàëüíîãî ñåïñèñà ó äîíîøåííûõ
Lower Vitamin D Levels Are Associated With Increased Risk of Early-Onset Neonatal Sepsis in Term Infants.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ýòî èññëåäîâàíèå ïîêàçàëî âïåðâûå, ÷òî ó ìàòåðè è íîâîðîæäåííîãî óðîâíè 25-OHD áûëè çíà÷èòåëüíî íèæå ó äîíîøåííûõ äåòåé, êîòîðûå áûëè ãîñïèòàëèçèðîâàíû ñ Early-Onset Neonatal Sepsis (EOS-ðàííèé íåîíàòàëüíûé ñåïñèñ ). Óðîâíè íåîíàòàë. 25-OH D áûëè ïîëîæèòåëüíî êîððåëèðóåò ñ ìàòåð. óðîâíåì25-OHD. Óðîâíè 25-OHD áûëè òàêæå âûøå ëåòîì è ïðè ðåãóëÿðíîì ïðèåìå âèòàìèííûõ äîáàâîê. Ýòè äàííûå ñâèäåòåëüñòâóþò î òîì, ÷òî ðåãóëÿðíîå äîáàâëåíèå âèòàìèíà D âî âðåìÿ áåðåìåííîñòè ìîæåò áûòü ïîëåçíûì äëÿ ïðåäîòâðàùåíèÿ EOS ó äîíîøåííûõ íîâîðîæäåííûõ.

 ïîñëåäíèå ãîäû, íîâûå äàííûå ïîääåðæèâàåò èììóíîìîäóëèðóþùåå äåéñòâèå âèòàìèíà D íà èììóííóþ ôóíêöèþ.  äîïîëíåíèå ê ñèñòåìíîé âîñïàëèòåëüíîé ðåàêöèè ìîäóëÿöèè, âèòàìèí D òàêæå îêàçûâàåò âîçäåéñòâèå íà ìåñòíîì êîíòðîëÿ ïàòîãåíîâ. Âèòàìèí D, êàê ñîîáùàåòñÿ, ïîäàâëÿþò ðîñò øòàììîâ çîëîòèñòîãî ñòàôèëîêîêêà, Ñ. Ïèððîëèäîíèëïåïòèäàçà, Ê. ïíåâìîíèè è Å.coli. Âèòàìèí D òàêæå ïðåäîòâðàùàåò ïðÿìîå âòîðæåíèå áîëåçíåòâîðíûõ áàêòåðèé çà ñ÷åò ïîâûøåíèÿ êëèðåíñà èç íèõ âòîðæåíèå îðãàíèçìû íà òàêèõ óðîâíÿõ, êàê äûõàòåëüíûå ïóòè. Êðîìå òîãî óðîâåíü âûøå âèòàìèíà Ä ó áåðåìåííûõ æåíùèí áûëè ñâÿçàíû ñ áîëåå íèçêîé ïðîöåíòíîé Ãðóïïà B ñòðåïòîêîêêîâ âëàãàëèùà çàðàæåíèå.
Õîòÿ 25-OHD ìîãóò áûòü ñèíòåçèðîâàòü ïëîäà ïî÷êè, óðîâåíü íåîíàòàëüíîé âèòàìèíà D, ïðåæäå âñåãî, çàâèñèò è êîððåëèðóåò ñ ìàòåðèíñêèì óðâíåì âèòàìèíà D ïðè ðîäàõ, ïîêà ðåáåíîê íå íà÷íåò ïîëó÷àòü âèòàìèí D èç äðóãèõ èñòî÷íèêîâ.  ñîîòâåòñòâèè ðåçóëüòàòû ïîêàçàëè êîððåëÿöèþ ìåæäó ìàòåðèíñêîé è íåîíàòàëüíîé óðîâíåé 25-OHD êàê ïîñëåäíèé áûë çíà÷èòåëüíî íèæå ó äåòåé, ðîæäåííûõ îò ìàòåðåé ñ áîëåå íèçêèìè óðîâíÿìè 25-OHD.  ïðåäûäóùåì èññëåäîâàíèè, 25-OHD óðîâíè îêàçàëèñü âûøå ó çäîðîâûõ ìëàäåíöåâ ïî ñðàâíåíèþ ñ òåìè, êòî áûë îñòðûé èíôåêöèè íèæíèõ äûõàòåëüíûõ ïóòåé. Êðîìå òîãî, ó íîâîðîæäåííûõ, ó êîòîðûõ íå áûëî èíôåêöèè, èìåëè çíà÷èòåëüíî áîëåå âûñîêèå óðîâíè 25-OHD ïî ñðàâíåíèþ ñ òåìè, êòî ñ EOS.  ðåçóëüòàòå, ìîæíî ïðåäïîëîæèòü, ÷òî ÝÎÑ ìîãóò áûòü ñâÿçàíû ñ ìàòåðèíñêîé è íåîíàòàëüíîé äåôèöèòà âèòàìèíà D. è, ñëåäîâàòåëüíî, ìîæåò áûòü ðàçóìíûì, ÷òîáû ðåêîìåíäîâàòü âèòàìèíà D. âñåì áåðåìåííûì æåíùèíàì äëÿ ïðåäîòâðàùåíèÿ EOS â èõ äåòåé.

Âèòàìèí D äåôèöèò ðàñïðîñòàíåí âî âðåìÿ áåðåìåííîñòè îò 18 äî 84% â çàâèñèìîñòè îò ñòðàíû è ìåñòíûõ îáû÷àåâ îäåæäû.  ïîñëåäíèå ãîäû èññëåäîâàíèÿ èç ðàçíûõ óãîëêîâ Òóðöèè ñîîáùèëè î ñåðüåçíîì äåôèöèò âèòàìèíà D (25-OHD óðîâíè <10 íã ìë-1) â 46 äî 80% áåðåìåííûõ æåíùèí è êîðìÿùèõ ìàòåðåé, â èññëåäîâàíèè, ïðîâåäåííîì â ýòîì æå ðåãèîíå Òóðöèè, íèçêèå óðîâíè ìàòåðèíñêîé 25-OHD áûëè íàéäåíû, ñâÿçàíî ñ íèçêèì óðîâíåì îáðàçîâàíèÿ, íåäîñòàòî÷íîå ïîòðåáëåíèå âèòàìèíà D è ïðèâû÷êè îäåâàòüñÿ.

Âèòàìèí D Äåôèöèò áûë êëàññèôèöèðîâàí íà òðè ãðóïïû: îñòðàÿ íåäîñòàòî÷íîñòü (25-OHD óðîâåíü <10 íã ìë-1), íåäîñòàòî÷íîñòü (îò 11 äî 32 íã ìë-1) è àäåêâàòíîñòè (îò 32 äî 100 íã ìë-1).÷èñëî äåòåé ñ óðîâíåì 25-OHD <10 íã ìë-1 áûëà çíà÷èòåëüíî âûøå â ñåïñèñà ãðóïïå ïî ñðàâíåíèþ ñ êîíòðîëüíîé ãðóïïîé â èññëåäîâàíèè , Òàêèì îáðàçîì ðåçóëüòàòû ïîêàçûâàþò, ÷òî òÿæåñòü äåôèöèòà âèòàìèíà D. ïîâûøàåò ðèñê EOS â ýòèõ ìëàäåíöåâ. Ýòè äàííûå ñâèäåòåëüñòâóþò î âàæíîñòè àäåêâàòíîãî âèòàìèíà D. âî âðåìÿ áåðåìåííîñòè.

Êàê óêàçàíî âûøå, âèòàìèíà Ä ñîñòîÿíèå íîâîðîæäåííîãî ïðè ðîæäåíèè â ïåðâóþ î÷åðåäü çàâèñèò îò ñîñòîÿíèÿ âèòàìèíà D ìàòåðè â ïåðèîä áåðåìåííîñòè. Íîâûå äàííûå ïîäòâåðæäàþò óëó÷øèòü ïèòàòåëüíóþ ìàòåðèíñêîé ñòàòóñ âèòàìèíà D äëÿ óëó÷øåíèÿ ðåçóëüòàòîâ ðîäîâ. Òàêèì îáðàçîì, âàæíî óñòàíîâèòü îïòèìàëüíîå êîëè÷åñòâî ïîòðåáëåíèÿ âèòàìèíà D äëÿ ïîääåðæàíèÿ àäåêâàòíîãî óðîâíÿ äëÿ ïðåäîòâðàùåíèÿ ìàòåðèíñêîé è íåîíàòàëüíîé äåôèöèòîì âèòàìèíà D è ïîñëåäóþùèõ íåáëàãîïðèÿòíûõ ïîñëåäñòâèé äëÿ çäîðîâüÿ. Òåêóùèå ðåêîìåíäàöèè ïîòðåáëåíèå âèòàìèíà D âî âðåìÿ áåðåìåííîñòè äèàïàçîíå îò 400 äî 600 ÌÅ â ñóòêè â 1500 äî 2000 ÌÅ â äåíü.  ïîñëåäíåå âðåìÿ äâà íîâûõ ðàíäîìèçèðîâàííûõ êîíòðîëèðóåìûõ èññëåäîâàíèé ïîêàçàëè, ÷òî åæåäíåâíîå ïîòðåáëåíèå âûøå (4000 ÌÅ â äåíü) âèòàìèíà D â ðåçóëüòàòå ñ áîëåå âûñîêîé öèðêóëèðóþùèå óðîâíè 25-OHD ó áåðåìåííûõ æåíùèí ïî ñðàâíåíèþ ñ íèçêèìè äîçàìè (200 ÌÅ â ñóòêè è 2000 ÌÅ â äåíü).
Òàêèì îáðàçîì, áûëî îòìå÷åíî, ÷òî âûøå äîçà âèòàìèíà D. ìîæåò ïîòðåáîâàòüñÿ äëÿ ïðåäîòâðàùåíèÿ ãèïîâèòàìèíîçà D è äîñòèæåíèÿ íîðìàëüíûõ öèðêóëèðóþùèõ 25-OHD óðîâíÿõ (îò 40 äî 60 íã ìë-1) âî âðåìÿ áåðåìåííîñòè, ÷òî òàêæå ñíèæàåò ÷àñòîòó ñîïóòñòâóþùèõ çàáîëåâàíèé áåðåìåííîñòè. [ çàêëþ÷åíèå, ýòî ïåðâîå èññëåäîâàíèå, êîòîðîå ñîîáùàåò çíà÷èòåëüíî áîëåå íèçêèå ìàòåðåé è íîâîðîæäåííûõ óðîâåíü 25-OHD ó äîíîøåííûõ ñ EOS ñðàâíåíèþ ñ òåìè, êòî íå èìåë ñåïñèñ. Óðîâíè íåîíàòàëüíîé 25-OHD õîðîøî êîððåëèðóåò ñ ìàòåðèíñêîé óðîâíÿõ. Óðîâíè 25-OHD áûëè íàéäåíû, ñâÿçàíî ñ ñåçîííîñòüþ, ðåãóëÿðíîå óïîòðåáëåíèå âèòàìèíà D, ñîöèàëüíî-ýêîíîìè÷åñêîãî ñòàòóñà è ïðåäïî÷òåíèé â îäåæäå ìàòåðè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #140  
Ñòàðûé 17.02.2015, 08:03
Oleg_Kon Oleg_Kon âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.04.2002
Ãîðîä: Åêàòåðèíáóðã
Ñîîáùåíèé: 65
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 25 ðàç(à) çà 22 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 19
Oleg_Kon ýòîò ó÷àñòíèê èìååò îòëè÷íóþ ðåïóòàöèþ íà ôîðóìå
Allergen Skin Prick Testing in Early Childhood: Reproducibility and Prediction of Allergic Symptoms into Study design
Êîãîðòà èç 200 íîâîðîæäåííûõ ñëó÷àéíûì îáðàçîì âûáðàíà äëÿ íàáëþäåíèÿ äî 20 ëåòíåãî âîçðàñòà. Èç íèõ 163 (82%) áûëî îáñëåäîâàíû â 5 ëåò, 150 (76%) â 11 ëåò è 164 (83%) â 20 ëåò ïðè ïîìîùè ïðèê-òåñòà íà 11 ñàìûõ ðàñïðîñòðàíåííûõ àëëåðãåíîâ. Òàêæå îöåíèâàëàñü ÷àñòîòà àòîïè÷åñêîãî äåðìàòèòà, àëëåðãè÷åñêîãî ðèíîêîíúþíêòèâèòà, ïîâòîðíîé îäûøêè è ñèïòîìîâ ïèùåâîé àëëåðãèè ïî äàííûì àíàìíåçå è êëèíè÷åñêîãî îñìîòðà â äèíàìèêå.
Ðåçóëüòàòû.
Ïîâòîðÿåìîñòü ïîçèòèâíûõ ðåçóëüòàòîâ êîæíûõ òåñòîâ â 5 ëåò áûëà 100% â âîçðàñòå 11 è 20 ëåò, ò.å. íèêòî èç äåòåé ñ ïîëîæèòåëüíûìè òåñòàìè íå ñòàë íåãàòèâíûì. ×àñòî ïîÿâëÿëèñü íîâûå âèäû ðåñïèðàòîðíîé ñåíñèáèëèçàöèè. Ïîëîæèòåëüíûå ïðèê-òåñòû â âîçðàñòå 5 ëåò ïðåäñêàçûâàëè àëëåðãè÷åñêèå ñèìïòîìû (êðîìå àòîïè÷åñêîãî äåðìàòèòà) â 11 ëåò (÷óâñòâèòåëüíîñòü 28%, ñïåöèôè÷íîñòü 94%) è â 20 ëåò (÷óâñòâèòåëüíîñòü 23%, ñïåöèôè÷íîñòü 91%).
Çàêëþ÷åíèå.
Ïîëîæèòåëüíûå êîæíûå ïðèê-òåñòû â 5 ëåò îáëàäàþò âûñîêîé ñòåïåíè ïîâòîðÿåìîñòè â 11 è 20 ëåò è àññîöèèðîâàíû ñ ðåñïèðàòîðíûìè àëëåðãè÷åñêèìè ñèìïòîìàìè (ðèíîêîíúþíêòèâèòû, àñòìà). Ìåæäó òåì, íåãàòèâíûå òåñòû â 5 ëåò íå èñêëþ÷àþò ïîÿâëåíèÿ ñåíñèáèëèçàöèè è àëëåðãè÷åñêèõ ñèìïòîìîâ â áîëåå ñòàðøåì âîçðàñòå.
Èñòî÷íèê:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #141  
Ñòàðûé 17.02.2015, 10:49
Oleg_Kon Oleg_Kon âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.04.2002
Ãîðîä: Åêàòåðèíáóðã
Ñîîáùåíèé: 65
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 25 ðàç(à) çà 22 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 19
Oleg_Kon ýòîò ó÷àñòíèê èìååò îòëè÷íóþ ðåïóòàöèþ íà ôîðóìå
Ìàêðîëèäû è ïèëîðîñòåíîç

Ðåòðîñïåêòèâíîå êîãîðòíîå èññëåäîâàíèå, ðîäèâøèõñÿ ìåæäó 2001 è 2012 ãîäàìè ïîêàçàëî ïîâûøåíèå ðèñêà âîçíèêíîâåíèÿ ïèëîðîñòåíîçà ïîñëå èñïîëüçîâàíèÿ âíóòðü ýðèòðîìèöèíà è àçèòðîìèöèíà â ïåðâûå 6 íåäåëü æèçíè (÷åì ìåíüøå âîçðàñò èñïîëüçîâàíèÿ ëåêàðñòâà, òåì ñèëüíåå àññîöèàöèÿ).
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Âïåðâûå î ñâÿçè ìåæäó ìàêðîëèäàìè â ïåðèîä íîâîðîæäåííîñòè è ïèëîðîñòåíîçîì ñòàëè ïèñàòü áîëåå 10 ëåò íàçàä (íàïðèìåð, àìåðèêàíñêîå èññëåäîâàíèå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ).
Ãîä íàçàä áûëè îïóáëèêîâàíû ðåçóëüòàòû áîëüøîãî äàòñêîãî èññëåäîâàíèÿ, â êîòîðîì ïðîñëåæèâàëàñü ñâÿçü ïèëîðîñòåíîçà ñ èñïîëüçîâàíèåì ìàêðîëèäîâ â ïåðâûå íåäåëè æèçíè, à òàêæå ëå÷åíèåì ìàêðîëèäàìè ìàòåðåé ñ ïîñëåäíèå íåäåëè áåðåìåííîñòè è âî âðåìÿ ëàêòàöèè ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ).
Ìåõàíèçìû âçàèìîñâÿçè ïîêà íå ÿñíû. Íåêîòîðûå èññëåäîâàòåëè ïðåäïîëàãàþò âîçìîæíîñòü ðàçâèòèÿ ðàáî÷åé ãèïåðòðîôèè ìûøö âûõîäíîãî îòäåëà æåëóäêà ïîä âîçäåéñòâèåì ìîòèëèíî-ïîäîáíîãî ýôôåêòà ìàêðîëèäîâ.
Ìàêðîëèäû èñïîëüçóþòñÿ â ïåðâûå ìåñÿöû æèçíè îáû÷íî äëÿ ëå÷åíèÿ õëàìèäèéíûõ èíôåêöèé è êîêëþøà.

Êîììåíòàðèè ê ñîîáùåíèþ:
ggg650 îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #142  
Ñòàðûé 19.02.2015, 10:46
Oleg_Kon Oleg_Kon âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.04.2002
Ãîðîä: Åêàòåðèíáóðã
Ñîîáùåíèé: 65
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 25 ðàç(à) çà 22 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 19
Oleg_Kon ýòîò ó÷àñòíèê èìååò îòëè÷íóþ ðåïóòàöèþ íà ôîðóìå
 ôåâðàëå â JAMA Dermatology îïóáëèêîâàíû ðåçóëüòàòû äåñÿòèëåòíåãî íàáëþäåíèÿ çà äåòüìè, ïîëó÷àâøèìè â êà÷åñòâå ëå÷åíèÿ àòîïè÷åñêîãî äåðìàòèòà ïèìåêðîëèìóñ (Ýëèäåë).  èññëåäîâàíèè ó÷àñòâîâàëî îêîëî 7, 5 òûñÿ÷ àìåðèêàíñêèõ äåòåé è ñðåäíåå êîëè÷åñòâî èñïîëüçîâàííîãî Ýëèäåëà ñîñòàâèëî 793 ãðàììà íà ðåáåíêà.  õîäå íàáëþäåíèÿ âûÿâëåíî 5 ñëó÷àåâ îïóõîëåé: äâå ëåéêåìèè, äâå ëèìôîìû è îäèí ðàê êîñòè. Íè îäíîãî ñëó÷àÿ ðàêà êîæè íå áûëî çàðåãèñòðèðîâàíî.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Íàïîìíþ, ÷òî Ýëèäåë áûë çàðåãèñòðèðîâàí U.S. Food and Drug Administration â 2010 ãîäó äëÿ ëå÷åíèÿ àòîïè÷åñêîãî äåðìàòèòà ó äåòåé ñ 2õ ëåò è â àííîòàöèè áûëî óêàçàíî î ïîòåíöèàëüíîì ðèñêå ðàêà êîæè.
Æäåì èçìåíåíèé â îôèöèàëüíûõ ðåêîìåíäàöèÿõ ïî ïðåïàðàòó.
Îòâåòèòü ñ öèòèðîâàíèåì
  #143  
Ñòàðûé 16.03.2015, 23:59
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,291
Ïîáëàãîäàðèëè 33,189 ðàç(à) çà 31,539 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íåäàâíÿÿ ïîëíîòåêñòîâàÿ ïóáëèêàöèÿ ñ îáçîðîì óæå èìåþùåéñÿ ëèòåðàòóðû ïëþñ ëè÷íûé îïûò àâòîðîâ:

Diagnosis and management of primary autoimmune neutropenia in children: insights for clinicians.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #144  
Ñòàðûé 16.04.2015, 09:49
Oleg_Kon Oleg_Kon âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.04.2002
Ãîðîä: Åêàòåðèíáóðã
Ñîîáùåíèé: 65
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 25 ðàç(à) çà 22 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 19
Oleg_Kon ýòîò ó÷àñòíèê èìååò îòëè÷íóþ ðåïóòàöèþ íà ôîðóìå
Ñòàòüÿ ñ ñàéòà Àìåðèêàíñêîé Àêàäåìèè ïåäèàòðèè, êàñàþùàÿñÿ ñîâðåìåííûõ ïîäõîäîâ ê âåäåíèþ àòîïè÷åñêîãî äåðìàòèòà. Skin-directed management of atopic dermatitis focus of new report [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Òåçèñíî:
Ïîÿâëÿþòñÿ íîâûå äîêàçàòåëüñòâà ðîëè íàðóøåíèÿ áàðüåðíîé ôóíêöèè êîæè â ïàòîãåíåçå àòîïè÷åñêîãî äåðìàòèòà, à èìåííî ðîëè áåëêà ôèëàããðèíà. Äî 50 % ïàöèåíòîâ ñ àòîïè÷åñêèì äåðìàòèòîì èìåþò ìóòàöèè â ãåíå, îòâå÷àþùåì çà ýòîò áåëîê (FLG ãåí). Íàðóøåíèÿ ôèëàããðèíà ìîãóò ðàçíûìè ñïîñîáàìè âëèÿòü íà ïðîãðåññèðîâàíèå àòîïè÷åñêîãî äåðìàòèòà. Íèçêîå ñîäåðæàíèå ôèëàããðèíà íàðóøàåò ñïîñîáíîñòü êåðàòèíîöèòîâ óäåðæèâàòü âîäó â êîæå, ÷òî âåäåò ê ñóõîñòè, çóäó è äåðìàòèòó. Ïðè íàðóøåíèè áàðüåðíîé ôóíêöèè êîæè àëëåðãåíû èç îêðóæàþùåé ñðåäû ëó÷øå ïðîíèêàþò âãëóáü êîæè è âûçûâàþò âîñïàëåíèå. Íåäîñòàòî÷íàÿ ïðîäóêöèÿ ôèëàããðèíà èçìåíÿåò ðÍ êîæè, ÷òî âûçûâàåò èçáûòî÷íûé ðîñò áàêòåðèé, êîòîðûå â ñâîþ î÷åðåäü çàïóñêàþ èììóííûé îòâåò â êîæå è äåðìàòèò.
×àñòîé îøèáêîé ÿâëÿåòñÿ ìíåíèå, ÷òî àòîïè÷åñêèé äåðìàòèò âûçûâàåòñÿ ïèùåé. Íà ñàìîì äåëå ñâÿçü ìåæäó àòîïè÷åñêèì äåðìàòèòîì è ïèùåâîé àëëåðãèåé ñëîæíà, íî çíà÷åíèå àëëåðãèè íà ïèùó ïåðåîöåíèâàåòñÿ. Õîòÿ ó äåòåé ñ àòîïè÷åñêèì äåðìàòèòîì ïèùåâàÿ àëëåðãèÿ âûÿâëÿåòñÿ íà 25-35% ÷àùå, ìîæíî ãîâîðèòü, ÷òî àëëåðãèÿ ñâÿçàíà ñ àòîïè÷åñêèì äåðìàòèòîì, íî íå îáÿçàòåëüíî ÿâëÿåòñÿ ïðè÷èíîé.
Î òîïè÷åñêèõ ñòåðîèäàõ.
Ñòåðîèäîôîáèÿ âîçíèêëà â îòâåò íà îïèñàíèå ïîáî÷íûõ ýôôåêòîâ, êîòîðûå èíîãäà âñòðå÷àþòñÿ ïîñëå èñïîëüçîâàíèÿ ìåñòíûõ ñòåðîèäíûõ ïðåïàðàòîâ âûñîêîé (íà ðîññèéñêîì ðûíêå - Ýëîêîì, Ôëóöèíàð, Àäâàíòàí, Öåëåñòîäåðì) è ìàêñèìàëüíîé àêòèâíîñòè (Äåðìîâåéò). Ìåæäó òåì, ñîãëàñíî èññëåäîâàíèÿì, òîïè÷åñêèå ñòåðîèäû íèçêîé (ãèäðîêîðòèçîíîâàÿ è ïðåäíèçîëîíîâàÿ ìàçü) è óìåðåííîé àêòèâíîñòè (Ëîêîèä, Àôëîäåðì, Ëîðèíäåí, Ôòîðîêîðò) ýôôåêòèâíûå è áåçîïàñíû ïðè èñïîëüçîâàíèè íàäëåæàùèì îáðàçîì.
Äëÿ ðîäèòåëåé âàæíî îáåðåãàòü êîæó ðåáåíêà îò êîíòàêòà ñ òðèããåðàìè èç âíåøíåé ñðåäû (ïûëüöà, ïûëü, ïëåñåíü, íåñïåöèàëèçèðîâàííûå ñðåäñòâà äëÿ óõîäà çà êîæåé, äåòåðãåíòû, ãðóáàÿ òêàíü, ñòðåññ, ïåðåãðåâàíèå).
Ïðèíöèïû ëå÷åíèÿ:
Ïîñòîÿííûé óõîä çà êîæåé, âêëþ÷àÿ âàííû ñ òåïëîé âîäîé è ìÿãêèìè ìîþùèìè ñðåäñòâàìè, çàòåì óâëàæíÿþùèå ñðåäñòâà. Èñïîëüçîâàíèå ìèíèìóì åæåäíåâíî ãèïîàëëåðãåííûõ ìàçåé è êðåìîâ ñ áîëüøèì êîëè÷åñòâîì ëèïèäîâ.
Èñïîëüçîâàíèå òîïè÷åñêèõ ïðîòèâîâîñïàëèòåëüíûõ ïðåïàðàòîâ òàêèõ êàê ñòåðîèäû íèçêîé èëè óìåðåííîé àêòèâíîñòè (íà ëèöî, øåþ, êîæíûå ñêëàäêè òîëüêî ïðåïàðàòû íèçêîé àêòèâíîñòè). Âîçìîæíà òåðàïèÿ òîïè÷åñêèìè èíãèáèòîðàìè êàëüöèíåâðèíà (íà ðîññèéñêîì ðûíêå - Ýëèäåë) è òåðàïèÿ âëàæíûìè îáåðòûâàíèÿìè. Ïðè îòñóòñòâèè ýôôåêòà îò ëå÷åíèÿ â òå÷åíèå 1-2 íåäåëü ïîâòîðíûé îñìîòð âðà÷à.
Êîíòðîëü çóäà àíòèãèñòàìèííûìè ïðåïàðàòàìè, íå ïðîâîöèðóþùèìè ñîíëèâîñòü, íî íå òîïè÷åñêèìè àíòèãèñòàìèííûìè (Ôåíèñòèë Ãåëü áåñïîëåçåí!). Ó÷èòûâàòü, ÷òî çóä óñèëèâàåòñÿ â íî÷íîå âðåìÿ.
Êîíòðîëü èíôåêöèîííûõ òðèããåðîâ, îáñëåäîâàíèå íà áàêòåðèàëüíóþ èíôåêöèþ êîæè (çîëîòèñòûé ñòàôèëîêîêê) è ïî íåîáõîäèìîñòè àíòèáèîòèêîòåðàïèÿ. Âîçìîæíû âàííû ñ àíòèñåïòèêîì (ðàçáàâëåííûé õëîðñîäåðæàùèé ïðåïàðàò) äëÿ ñêëîííûõ ê èíôåêöèÿì êîæè äåòåé.
P.S. Íåìíîãî îòñåáÿòèíû â ñêîáêàõ...

Êîììåíòàðèè ê ñîîáùåíèþ:
CMEX81 îäîáðèë(à):
luidhen îäîáðèë(à):
eduardshraibman îäîáðèë(à):
SergMak îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #145  
Ñòàðûé 16.04.2015, 10:05
Àâàòàð äëÿ SergDoc
SergDoc SergDoc âíå ôîðóìà
Ïðîâèíöèàëüíûé ïåäèàòð
      
 
Ðåãèñòðàöèÿ: 05.02.2009
Ãîðîä: Èâàíîâî; ÐÔ
Ñîîáùåíèé: 11,385
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 8,230 ðàç(à) çà 4,753 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 44
SergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íà ýòó òåìó íåäàâíî îïóáëèêîâàíî èíòåðåñíîå èññëåäîâàíèå ñðàâíåíèÿ ýôôåêòèâíîñòè è áåçîïàñíîñòè ñòåðîèäîâ è ïèìåêðîëèìóñà

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

ðåçóëüòàòû î÷åíü ïðèÿòíûå ïîëó÷èëèñü

ïðè÷¸ì ïèìåêðîëèìóñ ïðèìåíÿëñÿ ñ 3 ìåñ. ýòî íå ïåðâîå òàêîå èññëåäîâàíèå, íî ñàìîå êðóïíîå. äîâîëüíî óäèâèòåëüíî ÷òî FDA äî ñèõ ïîð íàñòàèâàåò íà åãî çàïðåòå äî 2 ëåò

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
eduardshraibman îäîáðèë(à):
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè.
Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #146  
Ñòàðûé 24.04.2015, 23:00
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,291
Ïîáëàãîäàðèëè 33,189 ðàç(à) çà 31,539 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âåñüìà èíòåðåñíîå èññëåäîâàíèå ïðîâåëè áðàçèëüöû - îíè äàâàëè äåòÿì öèíê âíóòðü è â/âåííî (èç òåçèñîâ íå ñîâñåì ïîíÿòíî, çà÷åì áûë äîáàâëåí òàêîé ïóòü ââåäåíèÿ) â òå÷åíèå 3 ìåñ. è îòìåòèëè óâåëè÷åíèå èìè ïîòðåáëåíèÿ áåëêîâ è æèðîâ è ïðî÷èå ìàðêåðû. Êàê áû èçâåñòíî, ÷òî äåôèöèò öèíêà ìîæåò áûòü ïðèçíàêîì ïëîõîãî àïïåòèòà èëè äåòñêîé èçáèðàòåëüíîñòè â åäå, íî ÷òîáû òàê áûëî çàìå÷åíî, ÷òî äåòè èç ïðåèìóùåñòâåííî óãëåâîäíîé äèåòû ñòàëè äîáðîâîëüíî êóøàòü íîðìàëüíóþ åäó, ýòî âñòðå÷àþ âïåðâûå:

J Am Coll Nutr. 2015 Mar 11:1-10.
Effect of Zinc Supplementation on GH, IGF1, IGFBP3, OCN, and ALP in Non-Zinc-Deficient Children.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
eduardshraibman îäîáðèë(à):
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #147  
Ñòàðûé 30.04.2015, 11:07
Àâàòàð äëÿ SergDoc
SergDoc SergDoc âíå ôîðóìà
Ïðîâèíöèàëüíûé ïåäèàòð
      
 
Ðåãèñòðàöèÿ: 05.02.2009
Ãîðîä: Èâàíîâî; ÐÔ
Ñîîáùåíèé: 11,385
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 8,230 ðàç(à) çà 4,753 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 44
SergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
âîò è êîäåèí çàïðåòèëè

Åâðîïåéñêîå ìåäèöèíñêîå àãåíñòâî (European Medicines Agency, EMA) çàïðåòèëî èñïîëüçîâàíèå êîäåèí-ñîäåðæàùèõ ëåêàðñòâåííûõ ñðåäñòâ äëÿ ëå÷åíèÿ êàøëÿ è ïðîñòóäû ó äåòåé.

 ÷àñòíîñòè, â íîâîì çàÿâëåíèè EMA ñêàçàíî:

* Èñïîëüçîâàíèå êîäåèíà äëÿ ëå÷åíèÿ êàøëÿ è ïðîñòóäû ïðîòèâîïîêàçàíî äåòÿì äî äîñòèæåíèÿ âîçðàñòà 12 ëåò.
* Èñïîëüçîâàíèå êîäåèíà äëÿ ëå÷åíèÿ êàøëÿ è ïðîñòóäû íå ðåêîìåíäóåòñÿ ó äåòåé è ïîäðîñòêîâ â âîçðàñòå îò 12 äî 18 ëåò, êîòîðûå èìåþò ïðîáëåìû ñ äûõàíèåì.

Ýêñïåðòû EMA òàêæå çàÿâëÿþò, ÷òî êîäåèí íå äîëæåí áûòü èñïîëüçîâàí ó ïàöèåíòîâ ëþáîãî âîçðàñòà, åñëè èçâåñòíî, ÷òî îíè èìåþò ÷ðåçìåðíî áûñòðûé ìåòàáîëèçì êîäåèíà.

Êîäåèí â îðãàíèçìå ïðåîáðàçóåòñÿ â ìîðôèí. Ó íåêîòîðûõ ëþäåé, èìåþùèõ ñâåðõáûñòðûé ìåòàáîëèçì, ýòî ïðåîáðàçîâàíèå ïðîèñõîäèò áûñòðåå, ÷åì îáû÷íî, ÷òî ïðèâîäèò ê ðåçêîìó ïîâûøåíèþ óðîâíÿ ìîðôèíà â êðîâè, è çíà÷èòåëüíî óâåëè÷èâàåò ðèñê êðèòè÷åñêîãî óãíåòåíèÿ äûõàíèÿ è ñìåðòè. Ýòî ÿâëåíèå ñâÿçàíî ñ ïîëèìîðôèçìîì öèòîõðîìà P450 2D6 (CYP2D6).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè.
Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #148  
Ñòàðûé 01.05.2015, 00:41
SergMak SergMak âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 04.12.2011
Ãîðîä: Âèííèöà
Ñîîáùåíèé: 305
Ñêàçàë(à) ñïàñèáî: 28
Ïîáëàãîäàðèëè 138 ðàç(à) çà 104 ñîîáùåíèé
SergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Oleg_Kon Ïîñìîòðåòü ñîîáùåíèå
Ñòàòüÿ ñ ñàéòà Àìåðèêàíñêîé Àêàäåìèè ïåäèàòðèè, êàñàþùàÿñÿ ñîâðåìåííûõ ïîäõîäîâ ê âåäåíèþ àòîïè÷åñêîãî äåðìàòèòà. Skin-directed management of atopic dermatitis focus of new report [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Òåçèñíî:
Ïîÿâëÿþòñÿ íîâûå äîêàçàòåëüñòâà ðîëè íàðóøåíèÿ áàðüåðíîé ôóíêöèè êîæè â ïàòîãåíåçå àòîïè÷åñêîãî äåðìàòèòà, à èìåííî ðîëè áåëêà ôèëàããðèíà. Äî 50 % ïàöèåíòîâ ñ àòîïè÷åñêèì äåðìàòèòîì èìåþò ìóòàöèè â ãåíå, îòâå÷àþùåì çà ýòîò áåëîê (FLG ãåí). Íàðóøåíèÿ ôèëàããðèíà ìîãóò ðàçíûìè ñïîñîáàìè âëèÿòü íà ïðîãðåññèðîâàíèå àòîïè÷åñêîãî äåðìàòèòà. Íèçêîå ñîäåðæàíèå ôèëàããðèíà íàðóøàåò ñïîñîáíîñòü êåðàòèíîöèòîâ óäåðæèâàòü âîäó â êîæå, ÷òî âåäåò ê ñóõîñòè, çóäó è äåðìàòèòó. Ïðè íàðóøåíèè áàðüåðíîé ôóíêöèè êîæè àëëåðãåíû èç îêðóæàþùåé ñðåäû ëó÷øå ïðîíèêàþò âãëóáü êîæè è âûçûâàþò âîñïàëåíèå. Íåäîñòàòî÷íàÿ ïðîäóêöèÿ ôèëàããðèíà èçìåíÿåò ðÍ êîæè, ÷òî âûçûâàåò èçáûòî÷íûé ðîñò áàêòåðèé, êîòîðûå â ñâîþ î÷åðåäü çàïóñêàþ èììóííûé îòâåò â êîæå è äåðìàòèò.
×àñòîé îøèáêîé ÿâëÿåòñÿ ìíåíèå, ÷òî àòîïè÷åñêèé äåðìàòèò âûçûâàåòñÿ ïèùåé. Íà ñàìîì äåëå ñâÿçü ìåæäó àòîïè÷åñêèì äåðìàòèòîì è ïèùåâîé àëëåðãèåé ñëîæíà, íî çíà÷åíèå àëëåðãèè íà ïèùó ïåðåîöåíèâàåòñÿ. Õîòÿ ó äåòåé ñ àòîïè÷åñêèì äåðìàòèòîì ïèùåâàÿ àëëåðãèÿ âûÿâëÿåòñÿ íà 25-35% ÷àùå, ìîæíî ãîâîðèòü, ÷òî àëëåðãèÿ ñâÿçàíà ñ àòîïè÷åñêèì äåðìàòèòîì, íî íå îáÿçàòåëüíî ÿâëÿåòñÿ ïðè÷èíîé.
À ÿ îá ýòîì ãîä íàçàä ïèñàë: http://forums.rusmedserv.com/showpos...&postcount=115
Íî âíèìàíèÿ íèêòî îñîáî íå îáðàòèë
Îòâåòèòü ñ öèòèðîâàíèåì
  #149  
Ñòàðûé 06.05.2015, 22:45
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,291
Ïîáëàãîäàðèëè 33,189 ðàç(à) çà 31,539 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Î ïðèìåíåíèè ôòîðõèíîëîíîâ ó äåòåé ñ ïîçèöèè ýêñïåðòîâ ÂÎÇ:

Fluoroquinolone Use in Paediatrics: Focus on Safety and Place in Therapy (2011)
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #150  
Ñòàðûé 20.07.2015, 12:27
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Does Appendicitis Have to Be Treated With Surgery?

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Does Appendicitis Have to Be Treated With Surgery?
Antibiotic treatment of patients with computed tomography (CT)-proven, uncomplicated appendicitis may be as effective as appendectomy, according to a new study. The majority of patients randomly assigned to receive antibiotic treatment did not require an appendectomy during 1 year of follow-up, and those who did receive an appendectomy did not have significant complications. Despite this, when the two treatments were compared in a noninferiority trial, the investigators found that antibiotic treatment did not meet the prespecified criterion for noninferiority.
Another strength of the current study was the investigators' choice of antibiotics. They emphasized in their article that successful antibiotic treatment of appendicitis requires the selection of an antibiotic that provides broad-spectrum coverage of the many pathogens that might cause appendicitis.

The authors suggest that patients diagnosed with CT-proven uncomplicated acute appendicitis be given the opportunity to make an informed decision between antibiotic treatment and appendectomy.

Edward Livingston, MD, from Northwestern University Feinberg School of Medicine in Chicago, Illinois, and Corrine Vons, MD, PhD, from Johns Hopkins School of Medicine in Baltimore, Maryland, agree and penned an accompanying editorial to that effect. They write that, "[t]he time has come to consider abandoning routine appendectomy for patients with uncomplicated appendicitis. The operation served patients well for more than 100 years. With development of more precise diagnostic capabilities like CT and effective broad-spectrum antibiotics, appendectomy may be unnecessary for uncomplicated appendicitis, which now occurs in the majority of acute appendicitis cases."
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 05:52.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.